• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Apellis Pharmaceuticals, Inc. - Common Stock (NQ:APLS)

    40.91 +0.05 (+0.11%)
    Streaming Delayed Price Updated: 3:26 PM EDT, Apr 17, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 3,796,483
    Open 40.86
    Bid (Size) 40.91 (7,900)
    Ask (Size) 40.92 (2,300)
    Prev. Close 40.87
    Today's Range 40.85 - 40.95
    52wk Range 16.10 - 40.90
    Shares Outstanding 116,457,008
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Apellis Pharmaceuticals Inc (NASDAQ:APLS) Emerges as a Growth Stock with Bullish Technical Breakout Potential ↗
    Via Chartmill
    News headline image
    Halper Sadeh LLC is Investigating Whether APLS, CNTA, KZR, EQH are Obtaining Fair Deals for their Shareholders
    From Halper Sadeh LLC
    Via GlobeNewswire

    Performance

    YTD
    +58.2%
    +58.2%
    1 Month
    +117.4%
    +117.4%
    3 Month
    +99.3%
    +99.3%
    6 Month
    +69.4%
    +69.4%
    1 Year
    +125.3%
    +125.3%

    More News

    Read More
    News headline image
    Shareholder Alert: Ademi LLP investigates whether Apellis Pharmaceuticals Inc. is obtaining a Fair Price for Public Shareholders
    From Ademi LLP
    Via GlobeNewswire
    News headline image
    Why Biogen Stock Got Mashed on Monday ↗
    Via The Motley Fool
    News headline image
    Biogen Acquires Apellis Pharmaceuticals in $5.6 Billion Move into Immunology
    Via MarketMinute
    Apellis Pharmaceuticals (NASDAQ:APLS) Emerges as a Prime Affordable Growth (GARP) Candidate ↗
    Via Chartmill
    Apellis Pharmaceuticals Inc (NASDAQ:APLS) Reports Q4 2025 Earnings Beat Amid Mixed Revenue Results ↗
    Via Chartmill
    Topics Earnings
    News headline image
    The Coiled Spring: Why Small-Caps are Poised for a Generational Productivity-Led Surge
    Via MarketMinute
    Topics Artificial Intelligence Economy Stocks
    News headline image
    Halper Sadeh LLC is Investigating Whether APLS, CNTA, EQH, VYNE are Obtaining Fair Deals for their Shareholders
    From Halper Sadeh LLC
    Via GlobeNewswire
    News headline image
    Biogen Acquires Apellis Pharmaceuticals in $5.6 Billion Deal After Clinical Success
    Via MarketMinute
    News headline image
    Apellis Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Apellis Pharmaceuticals, Inc. - APLS
    From Kahn Swick & Foti
    Via Business Wire
    News headline image
    Why Biogen Stock Sank While the Market Soared on Thursday ↗
    Via The Motley Fool
    News headline image
    Halper Sadeh LLC is Investigating Whether APLS, CNTA, BIRD, WBD are Obtaining Fair Deals for their Shareholders
    From Halper Sadeh LLC
    Via GlobeNewswire
    News headline image
    Biogen's $5.6 Billion Acquisition of Apellis: A Strategic Pivot into Rare Kidney Diseases
    Via MarketMinute
    Let's have a look at the top gainers and losers one hour before the close of the markets of today's session. ↗
    Via Chartmill
    News headline image
    Spotlight Movers: APLS, VTIX, ELAB, ARTL Fuel Multi-Sector Momentum
    Via AB Newswire
    These stocks are making the most noise in today's session. ↗
    Via Chartmill
    Which stocks are experiencing notable movement on Tuesday? ↗
    Via Chartmill
    The market is filled with gapping stocks in Tuesday's session. ↗
    Via Chartmill
    Discover the top movers in Tuesday's pre-market session. ↗
    Via Chartmill
    News headline image
    APLS Stock Alert: Halper Sadeh LLC is Investigating Whether Apellis Pharmaceuticals, Inc. is Obtaining a Fair Price for its Shareholders
    From Halper Sadeh LLC
    Via Business Wire
    News headline image
    Biogen to Acquire Apellis, Enhancing the Company’s Growth Portfolio in Immunology and Rare Disease, Bolstering Growth Outlook and Accelerating Expansion into Nephrology
    From Apellis Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    This New $193 Million Bet Targets a Biotech With $689 Million in Revenue and a Potential Turnaround Story ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Apellis Announces Mikael Dolsten, M.D., Ph.D., to Join Board of Directors
    From Apellis Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Apellis (APLS) Q4 2025 Earnings Call Transcript ↗
    Via The Motley Fool
    Topics Earnings

    Frequently Asked Questions

    Is Apellis Pharmaceuticals, Inc. - Common Stock publicly traded?
    Yes, Apellis Pharmaceuticals, Inc. - Common Stock is publicly traded.
    What exchange does Apellis Pharmaceuticals, Inc. - Common Stock trade on?
    Apellis Pharmaceuticals, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Apellis Pharmaceuticals, Inc. - Common Stock?
    The ticker symbol for Apellis Pharmaceuticals, Inc. - Common Stock is APLS on the Nasdaq Stock Market
    What is the current price of Apellis Pharmaceuticals, Inc. - Common Stock?
    The current price of Apellis Pharmaceuticals, Inc. - Common Stock is 40.91
    When was Apellis Pharmaceuticals, Inc. - Common Stock last traded?
    The last trade of Apellis Pharmaceuticals, Inc. - Common Stock was at 04/17/26 03:26 PM ET
    What is the market capitalization of Apellis Pharmaceuticals, Inc. - Common Stock?
    The market capitalization of Apellis Pharmaceuticals, Inc. - Common Stock is 4.76B
    How many shares of Apellis Pharmaceuticals, Inc. - Common Stock are outstanding?
    Apellis Pharmaceuticals, Inc. - Common Stock has 5B shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.